Windtree Therapeutics Inc WINT

Healthcare Biotechnology

Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Its lead product candidate, istaroxime, is a dual-acting agent being developed to increase blood pressure and improve cardiac function in patients with cardiogenic shock and to improve cardiac function in patients with acute heart failure (AHF) and reverse the hypotension and hypoperfusion associated with heart failure that deteriorates to cardiogenic shock. The Company also has a licensing business model with partnership out-licenses in place.

NDAQ:WINT - Post by User

Windtree Therapeutics Inc > WINT...... 50 : 1 RS eff today

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Feb 24, 2023 8:35am

118 Views

Post# 35302864

WINT...... 50 : 1 RS eff today

$0.16 x 50 = $8.00

900,000 shares o/s post RS

They did a great job laying everyone out with high priced paper....200 mil shs traded as high as $0.38

Now they will do a P.O....trust me (that's the plan) !

What a game !

<< Previous

Bullboard Posts

Next >>

A potential breakthrough in spinal cord and optic nerve injury treatment